ArticleScientific reports2026
A real-world study of oral low-dose metronomic vinorelbine in elderly patients with metastatic triple-negative breast cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This exploratory study aimed to describe the clinical activity and tolerability profile of oral low-dose metronomic vinorelbine in a real-world cohort of elderly patients with pretreated metastatic triple-negative breast cancer (TNBC). Elderly metastatic TNBC patients received oral vinorelbine 20 mg thrice a week until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoints were objective response rate (ORR), clinical benefit rate (CBR; CR + PR + SD for ≥ 6 months). The secondary endpoints were tolerability, progression-free survival (PFS), overall survival (OS), and prognostic factors. 37 patients with elderly metastatic TNBC were enrolled, with a median of 2 prior chemotherapy regimens for MBC. Median age was 69 years (95% Confdence Interval (CI) 48.6–63.1). Number of metastases ≥ 2 in 26 patients (70.3%). The ORR was 29.7%, the DCR was 70.3%, the CBR was 45.9%, the median PFS was 8 months and the median OS was 29 months. The most common adverse events (AEs) included neutropenia (45.9%), anaemia(43.2%), nausea/vomiting(40.5%), and diarrhea (10%), the grade 3/4 AEs were less.The COX multivariate analysis results showed that efficacy of metronomic chemotherapy were independent prognostic factors affecting the survival of patients (P < 0.05). Oral metronomic vinorelbine may represent a potential therapeutic option for elderly metastatic TNBC patients, demonstrating promising efficacy and a manageable safety profile in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.